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ABSTRACT 
 
 
Hepatitis C Virus (HCV) infects approximately 70 million people worldwide and chronic 
infection can lead to liver cirrhosis and hepatocellular carcinoma. HCV contains a 
perplexing protein that has a number of proposed functions. This protein, termed p7, is 
essential for virus infectivity in vivo, however its function is a matter of controversy. 
Research into the function of p7 has been limited because there are no reliable antibodies 
available for the visualization of this protein. The goal of this project was to establish a 
system that utilizes fluorescent unnatural amino acids in order to label p7 within the 
context of a replicating virus. Strategically placed mutations within the viral p7 protein 
were selected to test their amenability to incorporation of an unnatural amino acid.  In 
order to optimize the incorporation system, plasmids containing mutations in the viral 
core protein were synthesized for further screening of positions tolerable to substitution.  
Ultimately, we were successful in incorporating a fluorescent unnatural amino acid into 
the viral core protein in a single protein expression system. If we can successfully 
transfer this system back into the context of a replicating virus, this technique could be 
used to facilitate the study of viral proteins in HCV and other viruses.     
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Chapter 1: Introduction 
1.1 Overview 
Hepatitis C virus (HCV) is a global health concern with an estimated 70 million HCV 
infected adults or 2.5% of the world population1–7. Prevalence ranges between 1-3% of 
the population in most countries, with a notable difference in Egypt, where there is over 
20% prevalence due to negligence of sterility during parenteral antischistosomal therapy8.  
The prevalence of HCV in Canada is estimated to be 1.1% of the general adult 
population9,10. When compared to other infectious diseases, HCV infection causes more 
years of life lost in Canada due to complications associated with disease progression, 11. 
Prevalence rates are highest amongst people who inject drugs (PWID), making 
intravenous drug use the largest risk factor for HCV transmission12,13. Given that HCV is 
a blood-borne virus, blood transfusions were a leading cause of transmission prior to 
current screening methods8.  The role of sexual activity in transmission remains unclear 
and controversial1,14.  
1.2 Discovery of the Virus  
In 1975, what is now known as HCV infection was first described as Non-A, 
Non-B hepatitis (NANBH); serological tests uncovered that many cases of parenterally-
transmitted hepatitis were not due to Hepatitis A virus (HAV) or Hepatitis B virus 
(HBV)15.  It would not be referred to as “Type C” until the infectious agent responsible 
for this form of hepatitis was identified.  After many years of extensive research, a 
breakthrough came in 1989, when a group at the Chiron Corporation isolated the 
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etiological agent responsible for NANBH as a cDNA clone15. The group modified a 
standard cloning protocol developed to isolate DNA encoding unknown proteins.  
Modifying the protocol made it possible to isolate and characterize the unknown viral 
genome.  Large volumes of infected chimpanzee plasma showing high infectious titre 
were ultracentrifuged to extract nucleic acids from the pelleted material.  A denaturation 
step was included to allow both RNA and DNA to act as a template given that the nature 
of the viral genome was not known at this time.  A cDNA library was derived from the 
isolated nucleic acids and inserted into the bacteriophage λgt11 to be expressed in 
Escherichia coli.  Antisera was required for screening the cDNA library, so serum was 
collected from a NANBH-positive patient as a source of antiviral antibodies.  Following 
immunoscreening of the cDNA library, which contained approximately 1 million clones, 
a single reactive clone termed 5-1-1, was found to be derived from the HCV genome.  
Further experiments on the clone confirmed it was not from the host genome and no 
homologous DNA sequences were found.  Cloned cDNA hybridized to RNA extracted 
from infected chimpanzee sera, but not to RNA extracted from control, uninfected 
chimpanzees.  HCV was confirmed as an RNA virus when hybridization signals were lost 
following treatment with ribonuclease but not with deoxyribonuclease.  Further 
experiments also confirmed that it was positive sense, single-stranded and large in length 
(~10,000 nucleotides).  The group postulated that HCV belonged to the Flaviviridae 
family of viruses due to sequence similarity.  Based on this work, the etiological agent 
responsible for NANBH was identified as HCV15. 
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HCV is divided into seven distinct genotypes (1-7) with each genotypic group 
containing various subtypes (a, b, c etc.)2,16.  Despite patients being diagnosed with a 
specific genotype, multiple HCV quasispecies can be found within each individual 
patient due to the error-prone nature of the viral polymerase17.  The estimated viral 
production rate of 1012 virions per day, and the estimated error rate of the polymerase, 
contribute to the number of mutations that can occur and could exist in every patient 
every day18.    
1.3 Natural History of Infection 
HCV infection varies widely within the infected population, as progression from 
acute to chronic infection is influenced by many host and viral factors11,19.  Generally, 
acute infection presents with little or no symptoms, making it very difficult to diagnose, 
increasing the likelihood of disease progression20–23.  In the absence of treatment, 
approximately 15-25% of cases of acute infection will resolve spontaneously, while 75-
85% of infected individuals will develop chronic HCV infection (Fig. 1.1)24.  Despite the 
high prevalence of cases that progress to chronic infection recent advances in 
pharmaceutical interventions for treatment of HCV-infected individuals have made 
clearance of the virus, or sustained virological response (SVR), more common20,25,26.  
Although treatments are available and effective, progression to chronic HCV infection 
can still lead to a plethora of complications, including the development of liver cirrhosis, 
fibrosis and an increased risk of hepatocellular carcinoma27,28.  The complications 
associated with chronic infection are what makes HCV infection a leading cause of liver-
related deaths worldwide11.  
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Figure 1.1 Flow Chart of Viral Infection and Related Outcomes (modified from 25).  
Diagnosis of HCV generally occurs during chronic stages when infected individuals 
begin to present symptoms of liver disease.   
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1.4 Viral Genome  
Since first being cloned in 1989, the viral genome of HCV has now been well 
characterized.  HCV is a 9.6 kilobase (kb), single-stranded, positive-sense RNA virus 
belonging to the Flaviviridae family15.  HCV has a single, long open-reading frame 
(ORF) encoding a polyprotein of approximately 3000 amino acids29.  In addition to the 
ORF, there is a 5’-noncoding region (NCR), which contains an internal ribosome entry 
site (IRES) and a conserved region at the 3’ end necessary for genome replication29. The 
IRES mediates synthesis of the HCV polyprotein, which is then cleaved by cellular and 
viral proteases into 10 viral proteins30,31.  The amino terminal region encodes the three 
structural proteins: the core (C) protein, and two envelope proteins, E1 and E2.  
Following the structural proteins is a small, integral membrane protein, termed p732.  
After p7, the remainder of the genome encodes the six non-structural (NS) proteins: NS2, 
NS3, NS4A, NS4B, NS5A, and NS5B (Fig. 1.2)32.   
1.5 Life cycle  
1.5.1 Virion Structure, Receptor Binding, Entry and Fusion  
The HCV virion is made up of a nucleocapsid comprised of core protein and a single 
copy of the RNA genome33,34.  The nucleocapsid is surrounded by a lipid envelope, 
envelope proteins E1 and E2, and host low-density lipoproteins (LDL) (Fig. 1.3)33.  The 
virus is classified as a lipoviral particle (LVP), due to its low buoyant density caused by 
inclusion of serum lipoproteins in the virion membrane35–37.  The presence of LDL in the 
virion is a common characteristic of Flaviviruses, and facilitates endocytosis through 
interactions with LDL receptors on target host cells38.   
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Figure 1.2 HCV Genome and Proteins (39).  The HCV genome is approximately 9.6 kb 
and contains a single open-reading frame encoding ten viral proteins.  The 5’-noncoding 
region contains the IRES.  HCV contains 3 structural proteins, core, envelope protein 1 
and envelope protein 2, and six non-structural proteins, NS2, NS3, NS4A, NS4B, NS5A, 
and NS5B.  For the purposes of this figure, p7 was included in the non-structural 
proteins, however, it is still unclear whether p7 is structural or non-structural.   
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Figure 1.3 HCV Structure (modified from (33)).  The HCV virion is comprised of a 
single strand of positive-sense RNA contained within a nucleocapsid.  The viral envelope 
is made up of viral proteins E1 and E2.   
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Figure 1.2. HCV Virion (adapted from (136)). HCV is an enveloped virus with a 
singl strand of positive-s nsed RNA enclosed in the nucleocapsid.  
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Many cell surface molecules have been proposed to mediate HCV binding.  
Cluster of Differentiation 81 (CD81), a member of the tetraspanin superfamily, has been 
shown to mediate cell binding of HCV E2 and was the first receptor to be identified as  
necessary in HCV infection40.  In addition to CD81, scavenger receptor B type I (SR-BI) 
was also proposed as a surface molecule functioning in binding of HCV through 
interactions with E241.  LDLs present on the LVP play a large role in facilitating HCV 
entry through the LDL receptor, and a recognition step preceding infection is modulated 
by glycosaminoglycan receptors38,42.    
The late steps of HCV entry were shown to be mediated by tight junction 
proteins, claudin-1 (CLDN1) and occludin43,44.  Evidence that Claudin-1 plays a key role 
in entry was confirmed as it can be used to make non-hepatic cell lines susceptible to 
HCV infection43.  Following the discovery of the role for claudin-1 in entry, another tight 
junction protein, occludin, was identified, confirming the importance of HCV entering 
through the tight junction44.   
HCV entry is ph-dependent (acidic conditions) and occurs via endocytosis33,45,46.  
Thus far, the specific mechanism of fusion is poorly understood, however, research 
suggests that the host receptors identified play key roles in the conformational changes of 
the envelope glycoproteins that lead to fusion and release of the nucleocapsid45,47–49.  
Both E1 and E2 have been proposed as fusion proteins responsible for the release of the 
nucleocapsid50–52.  Fusion of the virion via cellular receptors, endocytosis and entry into 
hepatocytes is depicted in (Fig. 1.4).  
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Figure 1.4 HCV Life Cycle (modified from (33)). HCV enters hepatocytes via receptor-
mediated endocytosis, with the proposed cell surface molecules CD81, SR-BI, OCDN, 
and CLDN1. The positive-strand genomic RNA is released into the cytoplasm and 
translation produces the polyprotein that will be proteolytically cleaved to release the 
viral proteins.  The replication forms with the non-structural proteins, excluding NS2, and 
the two step replication process is catalyzed by NS5B.  Core protein interacts with lipid 
droplets and the positive-strand RNA is then assembled into virions.  Following 
assembly, mature virions are released from the hepatocyte.   
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1.5.2 Translation 
Once the nucleocapsid has been released, the positive-strand genomic RNA is 
liberated into the cytoplasm32,53.  The 5’ terminal IRES initiates translation of the RNA 
genome generating a polyprotein that is co- and post-translationally cleaved by viral and 
host proteases29.  Host proteases act to cleave the structural region of the polyprotein, NS 
proteins are cleaved through the activity of NS2 cleaving itself from NS3 and NS3/4A 
acting on the remainder of the polyprotein cleavage sites53–56.  
1.5.3 RNA replication 
The non-structural proteins, with the exception of NS2, form a membrane-associated 
multiprotein complex which acts as the replication complex in HCV57,58.  These 
complexes associate with a virally-induced rearrangement of the endoplasmic reticulum 
(ER), the membranous web59,60. This rearrangement of the ER increases the concentration 
of metabolites and viral proteins58. 
Replication of the HCV genome occurs in two steps61–64.  The main protein 
involved in catalyzing replication is NS5B, the RNA-dependent, RNA polymerase 
(RdRp)65.  The first step utilizes the positive-strand genomic RNA as a template for 
synthesis of a negative-strand intermediate66.  In the second step, the negative-strand 
intermediate is used as the template to produce large amounts of positive-strand RNA66. 
The positive-strand RNA is utilized for polyprotein translation and synthesizing new 
replication intermediates and gets packaged into new virus particles67.  
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1.5.4 Assembly and Release  
Assembly is dependent on merging of the structural proteins, a newly synthesized RNA 
genome, and several host proteins that impart the low density of the LVP42.  HCV 
assembly begins with the viral core protein interacting with cytosolic lipid droplets 
(cLDs), which are thought to act as the platform for nucleocapsid formation68,69.  
Interactions with core protein at cLDs are necessary for the viral RNA to be included in 
assembly.  Core and NS5A mediate the association of the replication complex with 
cLDs70–72.  The envelope glycoproteins E1 and E2 are translated and remain associated 
with the ER membrane during this process73.  In addition to host and structural proteins, 
the non-structural proteins also play key roles in the process of assembly.  NS2 has been 
proposed to coordinate the interaction of the non-structural proteins involved in assembly 
and the envelope proteins, playing a key role during the early stages of assembly74–76. The 
enigmatic protein p7 has also been proposed to play a role in assembly based on 
mutational studies, however p7’s function has yet to be fully characterized77–79. A study 
utilizing chimeric genomes encoding structural and non-structural proteins showed that 
interactions between NS2 and NS3 and also between NS2, E1 and p7 are essential for 
virus assembly and/or release75.  Mutation, deletion and adaptive studies support the 
proposal that NS3 helicase activity plays a major role in assembly in concert with the 
NS4A cofactor33.  A study demonstrated that an assembly-defective NS4A mutant can be 
rescued by an NS3 mutation outside of the protease domain supporting the theory that 
these two non-structural proteins interact during assembly80.  
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NS5A plays a multitude of roles during the viral life cycle and interacts with 
numerous host and viral proteins.  It has been suggested that phosphorylation of residue 
457 in domain III of NS5A plays and important regulatory step in infectious virus 
production81.  In addition, domain III of NS5A functions in the unloading of core protein 
from lipid droplets, suggesting that interactions between these two proteins is linked with 
virus production efficiency82.  Despite the current body of evidenceassembly is a 
complex and highly organized process that remains to be fully defined.   
1.6 History of HCV Therapies 
1.6.1 Interferon and Ribavirin 
 
The standard of treatment for HCV infection has changed over the course of the 
last four decades83. The treatment regimen for HCV began in the 1980s as a 
monotherapy, consisting of treatment with recombinant interferon alpha (IFNα)84,85.  
IFNα was initially used to control the hepatic manifestations caused by NANBH, and 
liver enzyme tests and histological analysis were used to assess the primary outcomes86.  
In 1998, the standard of care evolved with the addition of RBV to the IFN 
monotherapy87. With the addition of RBV, the response rate to treatment approximately 
doubled, however, this was also accompanied by additional side effects.  The next 
breakthrough came in 2001 when the classical standard of care evolved one again with 
the approval of peg-IFN88.  The addition of these chemical groups increased the half-life 
of the protein in vivo by a substantial amount and peg-IFNα became the recommended 
treatment in combination with RBV89,90. Prior to the discovery of direct-acting antivirals 
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(DAA) therapies for HCV in 2011, the recommended standard of care for HCV infection 
was pegylated-interferon α (peg)-IFNα plus Ribavirin (RBV).    
1.6.2 Direct-Acting Antivirals  
The most promising treatment successes have come with the discovery of various DAAs 
that target multiple points during the HCV life cycle.83,91  The first compounds to be 
approved in 2011, Telaprevir and Boceprevir, quickly became integrated into the 
standard of care for genotype-1 patients along with the classical peg-IFNα and RBV92–94.  
Both Telaprevir and Boceprevir are NS3/4A protease inhibitors (PI) that act on the 
proteolytic active site of NS395.  Following the success with the first wave of PIs, a 
second generation of optimized compounds are in clinical development (as reviewed in 
96).  The approval of these compounds marked a major breakthrough in the field of 
antiviral pharmaceutics, since they were the first successful inhibitors specifically 
designed to cure a chronic infection and result in significantly improved SVR rates in 
populations infected with HCV genotype-196.   
 The next big breakthrough in HCV treatment came in 2010 with the discovery of 
Sofosbuvir and subsequent FDA approval in 201397,98.  Sofosbuvir differs from the first 
class of DAAs given that it acts as a nucleotide analogue, inhibiting polymerization after 
incorporation into a new viral RNA strand99.  This was also the first inhibitor to be used 
in combination with RBV in the absence of IFN, indicating the possibility of IFN-free 
therapies99.  This is of importance given that the side effects associated with IFN 
therapies can have an impact on compliance to treatment regimen.  As with the PIs, 
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Sofosbuvir also markedly improves SVR, albeit to a greater extent than is seen with the 
first-generation PIs and SVR can be achieved in a much shorter time frame100,101.   
In addition to the already-approved compounds, several NS5B inhibitors are also 
in clinical development but have yet to receive FDA approval102.  Many of the NS5B 
inhibitors are genotype-specific and most likely will only be useful in combination DAA 
therapy.  In recent years, several NS5A inhibitors, including Daclatasvir and Ledipasvir 
have become a focus for developing combination therapies99,103–107.  Although the 
mechanism of action is unknown, data suggests these compounds inhibit both replication 
and assembly.  The discovery and subsequent approval of these compounds highlights the 
drastic changes in the standard of care for HCV treatment83,108. Although these successful 
treatment options are now available, DAA therapy remains extremely expensive.  HCV 
will remain a health concern for North American healthcare systems until treatment is 
made widely available and affordable, and programs to reduce new infections are in 
place13,109. Furthermore, additional research is still needed to uncover other potential 
therapeutic targets.   
1.7 p7 protein 
p7 was first identified through expression of a series of C-terminally truncated 
HCV polyproteins fused to a human c-myc epitope tag39,78.  These studies showed p7 to 
be located between E2 and NS2 within the viral polyprotein76.  Homologous proteins 
have been identified in other viruses, such as bovine viral diarrhea virus, classical swine 
fever virus, and border disease virus, all containing a characteristic protein between E2 
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and NS239. Studies have shown that cleavage at the E2-p7 and p7-NS2 junctions is 
delayed, yielding a precursor E2-p7-NS2 polyprotein39,73. The function of this precursor 
polyprotein hasn’t been uncovered, however, the most likely hypothesis is that the 
polyprotein plays a regulatory role in viral kinetics or levels of final product expression.   
HCV p7 protein is a small, 63-amino acid residue protein, which spans the 
endoplasmic reticulum membrane twice, forming transmembrane domains 1 and 2 (TM1 
and TM2) connected by a short segment, termed the cytoplasmic loop, with its N- and C-
termini oriented toward the cytosol39.  Localization studies have found p7 in different 
areas of the cell.  Initial subcellular localization studies in HepG2 cells showed a large 
fraction of p7 in an early compartment of the secretory pathway, which suggests some 
sort of retention signal maintaining p7 localization in the ER110.  Conversely, p7 was 
shown to partially co-localize with mitochondria and adjacent membrane structures when 
green fluorescent protein (GFP)- or Flag-tagged p7 was visualized in HEK293T cells111.  
In addition, staining native p7 and tagged p7 demonstrated that untagged p7 was 
exclusively detected in the ER, whereas N-terminally-tagged p7 was detected in the ER 
or mitochondrial adjacent membranes111.  Work done with eGFP-p7 or p7 tagged with 
HA downstream of the potential E2-p7 cleavage site showed that p7 localized only in the 
ER of Huh-7 cells39.  This work suggests p7 localizes with multiple organelles indicating 
it may have a dual-role in HCV assembly and trafficking of nascent virions through 
cellular pathways.  However, the variation in p7 localization dependent on the tagging 
method used may also suggest that these tags disrupted p7 function and virus production.   
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Homologous proteins in other viruses, including the p7 protein in BVDV were 
originally proposed to oligomerize and form ion-channels (Fig 1.5)39.  Viral ion channels 
can play important roles in the virus’ life cycle, by regulating replication, or aiding in 
virus entry, assembly or release112.  Viral ion-channels could also modulate the 
electrochemical balance in subcellular compartments of host cells. This ion-channel 
activity was observed when p7 oligomerized to form a hexamer in artificial membranes 
and functioned as a calcium ion-channel in black lipid membranes39,78.  Black lipid 
membranes are a model system that can be used to characterize the physico-chemical 
properties of lipid membranes and can provide functional information regarding ion-
channels113.  Two drugs, amantadine and rimantadine, are ion-channel blockers that have 
been used to treat the influenza A virus by blocking the ion channel activity of the M2 
protein78,114.  The role of p7 as an ion-channel was confirmed when the ion-channel 
activity of p7 could be  blocked by amantadine and rimantadine78,114.  The ion-channel 
activity of p7 lead to classification of this protein as a viroporin39. Viroporins are small 
hydrophobic proteins with the ability to form pores or channels within membranes for ion 
and small molecule movement112.   
Studies performed in the chimpanzee model confirmed the role of p7 in 
infectivity77.  It was shown that any deletions or mutations in the cytoplasmic loop of p7 
within infectious clones of genotype 1a (G1a) failed to cause viremia after intrahepatic 
transfection of chimpanzees110.  In addition, substitution of G1a p7 with a p7 derived 
from a genotype 2a infectious 
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Figure 1.5 HCV p7 protein Monomer and Hexamer (Modified from 39) HCV p7 
protein is a polytopic membrane protein with two trans-membrane domains, TM1 and 
TM2, connected by a short segment, the cytoplasmic loop, with its N- and C-termini 
oriented toward the cytosol. HCV p7 can oligomerize to form a hexamer, which has been 
shown to have ion-channel activity.    
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clone was also not viable39.  These results demonstrated, in vivo, the importance of p7 in 
the virus life cycle and virus infectivity, however, the function of p7 remains unknown. 
Establishment of the HCV cell culture system allowed for mutational studies to be 
completed highlighting the importance of p7 for virus production38. One study supported 
a role for p7 at late stages in the viral replication cycle, given that mutants in p7 reduced 
total infectivity and the ratio of intracellular to released infectious particles. Current 
research suggests p7 does not play a role in viral entry or viral replication38. One study 
showed that the infectivity of released virions was maintained despite the fact that p7 had 
been mutated, demonstrating that it is most likely not acting during entry38.  Despite 
evidence supporting the importance of p7 for virus production, it is still unclear what role 
p7 does play38.  It has been suggested that p7 acts at a late stage in virus assembly, and 
may be acting as a dual function protein. One possible function of p7, in monomeric 
form, is assisting NS2 in gathering newly-formed capsids at LDs and glycoprotein 
complexes on the ER lumen for proper envelopment38.  Another possible function of p7, 
in oligomeric form, is protecting glycoproteins from immature degradation during 
trafficking and release through its ion-channel activity38.  Although there have been many 
proposed functions of p7, its role in the life cycle remains unknown. Since it has been 
shown that p7 plays a role in infectivity, it would be ideal to have a way of visualizing 
the protein, which would allow for better understanding of its function in the viral life 
cycle38.  Despite the body of evidence that currently exists surrounding HCV research, 
conventional tagging methods have made it difficult to study p7 and its function in the 
life cycle38. 
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1.7.1 Viral Protein Tagging Methods 
One traditional method of investigating protein function has been to label or tag 
the protein of interest with some sort of fluorescent moiety115. A commonly used method 
is epitope tagging, whereby a known epitope is fused to the protein of interest.  An 
epitope with available antibodies is selected, making it possible to detect proteins for 
which no antibody is available. The epitope-specific antibody will bind the epitope which 
is fused to the target protein116. One of the earliest used epitope tags was an epitope of the 
c-myc proto-oncogene product. This epitope tag has been used for immunohistochemical 
analyses, Western blots and subcellular localization studies.  The hemagglutinin antigen 
(HA) tag is one of the most used epitope tags and has been used for 
immunohistochemistry, immunoprecipitation and Western blot analyses. The FLAG 
epitope is a synthetic peptide that can be used by placing multiple copies in tandem for 
enhanced protein detection. Currently, GFP is one of the most widely used tags, given its 
inherent fluorescence.  GFP is a large protein that forms a “drum” structure, with 11 
sheets surrounding an -helix that sits diagonally across the inside of the “drum” and 
functions as a fluorophore113,114.  The fluorescent nature of GFP allows for the 
visualization and localization of proteins without the use of an antibody.  Although 
visualization studies using GFP can be conducted without an antibody, antibodies are 
available to be used for Western blot analysis and co-immunoprecipitation113,114. 
Although the technique of epitope tagging has facilitated the study of protein 
structure and function both in vitro and in vivo, there are some limitations and challenges 
associated with labelling. Despite numerous successes using the FLAG tag, there have 
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been complications, including reports of the FLAG tag disrupting activity when attached 
to the small GTPase H-Ras. The strategy of protein labelling by the fusion of an epitope 
to the target protein can be limited to either the C- or N-termini based on the epitope 
being used. Although GFP is extremely versatile, its large size can disrupt the structure 
and/or function of the target protein. The main limitation in using conventional tagging 
methods to study p7 is their large size and placement constraints116.  The limitations 
associated with conventional tagging methods supports the need for a new way of 
visualizing proteins that isn’t dependent on inserting a relatively large protein tag, which 
would facilitate the study of p7 and many other viral proteins.   
1.7.2 Unnatural Amino Acids to Visualize Proteins 
An alternative method for protein labelling involves the co-translational 
incorporation of a small unnatural amino acid (unAA) directly into the target protein in a 
site-specific manner.  One unAA of interest is p-Azido-L-phenylalanine (AzF), which was 
genetically encoded in M. jannaschii117,118.  AzF is an aryl-azide, one of the most widely 
used photocrosslinking agents 119 (Fig. 1.6). Photocrosslinkers can be used to 
photochemically label antibodies with hapten, irreversibly inactivate enzymes and probe 
protein-peptide and protein-protein interactions119.  In addition to photocrosslinking 
assays, AzF can be used in click chemistry reactions, whereby a fluorophore, or another 
convenient reactive moiety, can be attached to the side chain.  Probably the most 
interesting unAA available is Anap, 3-(6-acetylnapthalen-2-ylamino)-2-aminopropanoic 
acid, which is particularly interesting because of its fluorescent property (Fig. 1.6)120–123. 
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Anap is a derivative of prodan, an environmentally sensitive fluorophore that is 
commonly used in biochemistry and cell biology120.  
                      
 
Figure 1.6 Structure of p-Azido-L-phenylalanine (AzF: left) and 3-(6-
acetylnaphthalen-2-ylamino)-2-aminopropanoic acid (Anap: right) (Modified from 
119,120). AzF is an aryl-azide; upon irradiation with UV light at wavelengths below 310 
nm can form short-lived singlet nitrenes which will rearrange to form dehydroazepines.  
Dehydroazepines can react with amines to form robust adducts.  Aryl-azdes are 
commonly used as photocrosslinking agents to photochemically label antibodies, 
irreversibly inactivate enzymes and probe protein-peptide and protein-protein 
interactions.  Anap is an amino acid derivative of prodan, a fluorophore.  The absorption 
and emission maxima for Anap in water are 360 nm and 490 nm, respectively.  Anap is 
inherently fluorescent.   
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Anap is an ideal candidate for subcellular localization studies of proteins using site-
specifically incorporated Anap as a fluorescent reporter120.  Incorporating Anap into a 
protein would allow the protein to be visualized without the use of antibodies or fixing, 
since the Anap incorporated within the protein would be fluorescent itself.  Theoretically, 
any protein could be made fluorescent through the incorporation of Anap within the 
protein sequence.  The fluorescent properties of Anap make it a useful tool for studying 
protein folding and protein-protein interactions.  One group monitored protein misfolding 
by site-specifically labeling firefly luciferase with Anap122.  The group was able to track 
the thermal unfolding and aggregation of luciferase in vivo by analyzing the Anap 
fluorescence emission by confocal imaging.  The fluorescent properties of Anap will 
allow us to label proteins without the restrictions of conventional labeling methods.   
1.8 Translation  
In order to circumvent the issues mentioned above with the visualization of p7, 
we chose to employ a relatively novel strategy of protein labelling using unAA 
incorporation.  Proteins play a major role in all biological processes and amino acids are 
the building blocks required for protein formation.  
In order to understand how unAAs can be incorporated into proteins, we must 
first review basic protein synthesis124,125. Protein synthesis occurs through a step-wise 
process125.  First, DNA is transcribed yielding mRNA.  The process of transcription 
utilizes the DNA as a template strand and the resulting mRNA is a single-stranded 
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complementary copy of the gene.  This mRNA strand must next undergo a process 
known as translation, the decoding of mRNA to synthesize a protein. The decoding of 
mRNA relies on two major components, ribosomes and transfer RNAs (tRNA). tRNAs 
act as a bridge between mRNA codons and the specific amino acids that they code for 
and have two specialized ends. One end of the tRNA has a sequence of three nucleotides, 
the anticodon, which can bind the corresponding mRNA codon.  The opposite end of the 
tRNA carries the amino acid that is specified by the codons. An aminoacyl tRNA 
synthetase (synthetase) is the enzyme responsible for attaching the specified amino acid 
onto its tRNA. This process of amino acid binding to a tRNA is often referred to as 
“charging the tRNA”. Ribosomes are the structures where protein synthesis occurs, and 
where translation machinery is located.  Each ribosome has two subunits which will form 
around the mRNA, and act as a catalyst for amino acid linkage.  The process of 
translation can be broken down into three major steps: initiation, elongation and 
termination. Once all codons in the mRNA have been read by the tRNA molecules, and 
their corresponding amino acids linked together, the newly synthesized protein must be 
released from the mRNA and ribosome.  Termination of translation occurs once release 
factors bind to one of three termination codons and allows for the release of the mRNA 
from the ribosome.  The release of the mRNA from the ribosome also results in the 
dissociation of the ribosomal subunits. The three termination codons that are present at 
the end of a protein-coding sequence in mRNA are: UAA, UAG, and UGA.  These stop 
codons are not recognized by any endogenous tRNAs and the amber stop codon 
(TAG/UAG) is the least frequently used stop codon in the human genome.   
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1.9 UnAAs  
The genetic code consists of 64 triplet codons specific for 20 canonical amino 
acids and 3 stop signals126,127.  Although there are some variations of natural amino acids 
that have been identified, these changes arose through post-translational modifications of 
the canonical amino acids115,118,121,126–138.  Two amino acids, selenocysteine and 
pyrrolysine, have been deemed as natural expansions of the genetic code given that they 
can be incorporated into proteins co-translationally.  In addition to these naturally 
existing amino acids, there is a group of unAAs that can be incorporated into proteins 
yielding a variety of applications126,128. The applications of this technique are widespread 
given that there are over 100 unAAs with novel side chains including: bioorthogonal 
handles, photocross-linking moieties, fluorophores, and in vitro or cellular 
probes115,118,121,126–138. The incorporation of unAAs with these novel side chains can 
facilitate the study of proteins.  
Similar to natural amino acids, the genetic encoding of an unAA requires a set of 
specific components to ensure proper incorporation of the unAA at the desired location 
(Fig. 1.7)115,118,121,126–138.  The three requirements for unAA incorporation are a tRNA, a 
codon, and an aminoacyl-tRNA synthetase (hereafter referred to as synthetase).  This 
orthogonal tRNA/codon/synthetase set must be functionally compatible with other 
components of the translation apparatus and must not crosstalk with any endogenous 
tRNA/codon/synthetase sets.  The orthogonal tRNA must not be recognized by any  
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Figure 1.7 Unnatural Amino Acid Incorporation (modified from 136) UnAA 
incorporation occurs via the same process as natural amino acids. UnAA incorporation 
has three requirements for successful incorporation: a unique codon, an unAA that is 
stable in the cellular environment, and a tRNA/synthetase pair specific for only the 
unAA. Incorporation of an unAA uses the host cells translational machinery therefore the 
tRNA/synthetase must not bind any endogenous amino acids.   
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endogenous synthetase, and should decode only the orthogonal codon, which cannot be 
assigned to any canonical amino acid.  In order for the system to function properly, the 
orthogonal synthetase should only charge the orthogonal tRNA with the unAA.  Once the 
synthetase is expressed in cells, it can charge its orthogonal tRNA with the desired unAA.  
This process should result in the unAA being incorporated into proteins in response to the 
unique codon by utilizing the endogenous translational machinery115,118,121,126–138.   
In order to establish this technique, researchers had to perform very complex 
positive and negative selection to create tRNA/synthetase pairs that were specific for 
various unAAs (as reviewed in 136).  Only tRNA/synthetase pairs that could be used in 
conjunction with the endogenous translational machinery in different organisms would be 
considered successful134.  This technique has been applied to expand the genetic code of 
many cells ranging from bacteria, yeast, mammalian, stem cells and neurons to 
multicellular organisms including a primitive animal, an insect and a plant139. One group 
sought to expand the genetic code in the mouse (Mus musculus) brain using adeno-
associated viral (AAV) vectors for unAA incorporation137. Establishment of this system 
in the mouse brain meant that various unAAs could be incorporated and used as tools to 
probe and control protein functions in a live vertebrate.  Despite all of the work done, this 
technique remains to be applied to visualize viruses139. With the development of systems 
to incorporate unAAs into proteins, researchers have uncovered an innovative technique 
that can be utilized to both investigate and engineer protein structure and function. 
  27 
1.10 Project design and hypothesis 
As mentioned above, the function of HCV p7 is controversial, with the main 
reason for uncertainty that Western blots, immunoprecipitation and immunofluorescence 
cannot routinely be performed on p7, and due to the small size of p7 and inherent 
complications of protein tags, tagging studies have generated conflicting results.  
Researchers had to employ conventional tagging methods for p7 studies since there are 
no reliable antibodies available for the visualization of p7.  It has been shown that p7 may 
function in different ways based on the tagging method that was used.  We speculate that 
the tags were most likely interfering with protein structure or function39. This is likely 
due to the fact that the majority of the protein is buried within membranes in an infected 
cell. Another obstacle to studying the HCV p7 protein was the absence of a fully 
infectious cell culture system. Initially, HCV research was conducted using a replicon 
system, which utilized a neomycin selection gene and an ECMV IRES to mediate the 
translation of HCV NS proteins and enable replication in vitro. Despite its practical uses, 
the replicon system failed to produce infectious virus and did not express the viral 
structural proteins. Next, researchers established the HCV pseuoparticle system, which 
used retrovirus biology to create chimeric viruses containing the HCV glycoproteins on 
the surface.  This system was used for the generation of particles containing E1 and E2 
which could then be used to infect permissive hepatocytes to allow for the study of virus 
entry.  Up until 2005, all HCV research was conducted using the replicon and 
pseudoparticle systems.  Although both systems had their specific uses, neither system 
allowed for the study of p7. A major breakthrough came when the HCV cell culture 
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(HCVcc) system was discovered and provided the capacity to study the whole HCV life 
cycle, including assembly and release.  The establishment of the HCVcc system allowed 
researchers to study the viral proteins throughout the life cycle which has provided 
valuable knowledge into protein function and interactions39.   
The goal of this project was to develop a recombinant strain of HCV containing a 
fluorescent unnatural amino acid within p7 that would enable us to visualize this protein 
by immunofluorescence and confocal microscopy. The ability to visualize p7 within the 
context of a replicating virus would allow us to analyze p7 localization within the cell, as 
well as co-localization with other viral and cellular proteins, and all of these analyses 
could theoretically be performed in live cells. The availability of such a tool would allow 
us and others to study HCV proteins in a way that they’ve never been analyzed before, 
and ultimately, this strategy could then be applied to other viruses. 
1.11 Project aims 
I. Screening positions for unAA incorporation in the HCV p7 protein.  
Before testing incorporation of an unAA, we needed to select various positions 
throughout the HCV p7 protein.  These selected sites would then have a unique 
TAG codon inserted using site-directed mutagenesis to allow for incorporation of 
the unAA. A total of 14 sites were selected to be screened.  Once we selected the 
sites that would be used to screen amenability to unAA incorporation, we tested 
the system for incorporation of an unAA into the p7 protein in the context of a 
replicating virus. Following incorporation of the unAA during transfections, cells 
would be fixed and probed with a specific HCV core antibody to confirm virus 
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production in the presence of the unAA.  Theoretically, with the fluorescent 
unAA, we should visualize an overlap of green fluorescence from Anap, with the 
specific HCV core staining.   
  
II. Screening mutants for an amenable position in HCV core protein.  
Following challenges with unAA incorporation in the context of a fully 
replicating virus, we shifted our focus to testing incorporation in select core 
mutants in the context of a single-protein expression system.  We selected 11 
potential sites for incorporation of Anap in the HCV core protein. If any sites 
were found that could successfully incorporate the unAA, Anap, we would re-test 
those sites in the HCV core protein in a replicating virus.  Theoretically, if Anap 
can be incorporated at a specific position in the HCV core protein in a single-
protein expression system, it should also be possible for incorporation of Anap at 
that site in a replicating virus.  In addition, testing incorporation of Anap in a 
single-protein expression system first allows for optimization without the 
mutational pressure provided by the replicating virus.  
Chapter 2: Methodology  
2.1 Primer Design 
Individual mutagenic oligonucleotide primers were designed containing the 
desired mutation.  Special consideration had to be given to ensure all primers were 
approximately 30 bases in length while containing the mutation in the middle of the 
primer.  In addition, high GC content was desired while starting and terminating with at   
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Table 2.1 List of all primer sequences within p7  
 
Mutant  Primers (5’  3’) 
L755TAG CA GCA TTG GAG AAG TAG GTC GTC TTG CAC G 
L758TAG GAA GTT GGT CGT C TAG CAC GCT GCG AGT GC 
A761TAG CGT CTT GCAC GCT TAG AGT GCG GCT GAC TGC 
L769TAG GCT GAC TGC CAT GGC TAG CTA TAT TTT GCC 
Y771TAG CAT GGC CTC CTA TAT TAG TTT GCC ATC TTC TTC 
F772TAG CAT GGC CTC CTA TAT TAG GCC ATC TTC TTC G 
F775TAG C CTA TAT TTT GCC ATC TAG TTC GTG GCA GC 
F776TAG GCC ATC TTC TAG GTG GCA GCT TGG CAC ATC  AGG 
W780TAG C TTC TTC GTG GCA GCT TAG CAC ATC AGG GG 
T790TAG  GTG GTC CCC TTG TAG ACC TAT TGC CTC ACT GG 
Y792TAG GTC CCC TTG ACC ACC TAG TGC CTC ACT GGC 
W798TAG CTC ACT GGC CTA TAG CCC TTC TGC CTA CTG 
F800TAG GGC CTA TGG CCC TAG TGC CTA CTG CTC ATG GC 
P808TAG CTC ATG GCA CTG TAG CGG CAG GCT TAT GCC 
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least one G or C.  A complete list of primers can be found in Table 2.1.  All primers were 
purchased from Invitrogen.   
2.2 In-vitro Site-directed mutagenesis 
Plasmids were constructed using the QuikChange® II XL Site-directed 
Mutagenesis Kit (Strategene).  JFH1T was used as the dsDNA template (10ng) and was 
combined with the forward and reverse oligonucleotide primers containing desired 
mutations (100 ng), in a solution containing the 10X reaction buffer, dNTP mix, 
QuikSolution, ddH2O and PfuUltra HF DNA polymerase.  A three-segment thermal 
cycle was used to extend primers as per kit protocol. The 68°C temperature in the second 
segment was held for 13 minutes.  Following the thermal cycling Dpn-1 was added and 
incubated at 37°C for one hour in order to digest parental dsDNA.  
2.3 Transformation  
XL 10-gold ultracompetent cells were transformed upon addition of Dpn-1 treated 
DNA as per QuikChange® II XL Site-directed Mutagenesis Kit (Strategene) protocol.   
2.4 Miniprep DNA Purification 
Colonies were selected from transformed XL 10-gold ultracompetent cells and 
incubated overnight in 10 mL LB broth.  Plasmid DNA was isolated from bacteria culture 
via mini preparation using the QIAprep® Miniprep Kit (Qiagen).   
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2.5 PVUII Digestion 
Miniprep DNA samples and control plasmid (JFH1T) were treated with the 
restriction enzyme PVUII at 37°C for two hours, run on a 1.5% agarose gel, and analyzed 
by UV light to compare digestion patterns for initial screening of mutagenesis success.   
2.6 Sequencing of Plasmids 
Plasmids were sent for sequencing to the Centre of Applied Genomics.  For 
sequencing, the plasmid concentration was approximately 300 ng/μL.  Primers were 
diluted to a stock concentration of 5 ρmol in 0.7 μL and the diluted primer was used in 
sequencing reactions.  
2.7 Maxiprep DNA Purification 
Miniprep DNA samples containing the correct sequence were re-transformed in 
E. coli Dh5- competent cells and incubated overnight in 100 mL LB broth.  Plasmid 
DNA was isolated from bacteria culture via maxi preparation using QIAprep® Maxiprep 
Kit (Qiagen). 
2.8 Plasmid Linearization    
Plasmid DNA (25μg) was incubated at 37°C for 1 hour with 5 μL XbaI 
(Invitrogen), 5 μL BSA, 5 μL buffer and dH2O up to 50 μL.  Following the digestion, 
dH2O was added to increase volume to 100 μL followed by 100μL of 
phenol/chloroform/isoamyl alcohol (Invitrogen) and the sample was then mixed by 
vortex for 5 seconds.  Samples were spun in a table top microcentrifuge for 3 minutes at 
14,000xg. Next, 100 μL of upper phase was transferred to a new tube.  Then, 3 μL of 5 M 
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NaCl was added followed by 230 μL of 100% EtOH.  Samples were incubated at -20°C 
for 1 hour followed by a 5 minute spin at 14,000xg.  Supernatant was removed and the 
pellet was dried then resuspended in 30 μL of dH2O and DNA concentration was 
determined using a Nanodrop.  Linearized DNA was either stored at -20C or used 
directly for transcription.   
 
2.9 Cell Culture 
A human-hepatoma derived cell line (Huh-7.5) was cultured at 37°C in a 5% CO2 
incubator in 15 cm tissue culture dishes (Corning Incorporated). Cells were grown in 
Gibco® Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen) supplemented with 
10% heat-inactivated fetal bovine serum (FBS; Invitrogen) and antibiotics penicillin and 
streptomycin (PenStrep; Sigma) yielding complete medium (DMEM(comp)).  
Cells were passaged when cell growth reached approximately 75-90% confluency.  To 
passage cells, medium was removed from the culture dish and cells were treated with 
0.5% trypsin-EDTA (Invitrogen) and incubated at 37°C in 5% CO2 for 6 minutes. The 
plate was washed with 10 mL DMEM(comp) twice, and suspended cells were transferred to 
a 50 mL sterile polypropylene tube.  Cells were then centrifuged at 400xg for 5 minutes.  
Cell pellets were resuspended in 20 mL of DMEM(comp) Cells were counted using a 
hemocytometer and 2x106 cells were replated into culture dishes containing 25 mL of 
DMEM(comp).     
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2.10 DNA Transfection  
Huh-7.5 cells were seeded in 10 cm dishes at a density of 1x106 per dish 24 hours 
before DNA transfection.  Cells were washed twice and replaced with 2 mL of serum-
free (SF) media/plate.  Next, 500 μL of SF media and 20 μL of Lipofectamine®2000 
(Thermo Fisher Scientific) were combined with 500 μL of SF media and 1 μg of either 
pMah or pAnap and mixed gently. pMah is the plasmid that makes the tRNA and 
synthetase for incorporation of the unAA AzF; pAnap is the plasmid that makes the 
tRNA and synthetase for incorporation of the unAA Anap. Transfection mixes were then 
added to cells and incubated for 3 hours.  Following incubation, cells were washed twice 
and 7 mL of DMEM(comp) was added to each plate.  Transfected cells were incubated for 
24 hours to allow expression of the plasmid (pMah or pAnap) before transfection with 
viral RNA.   
2.11 Transcription  
On the day of transfection, 1 μg of linearized DNA was transcribed using the T7 
RiboMAX™ Express Large Scale RNA Production System (Promega) following the kit 
protocol.   
2.12 RNA Transfection 
Huh-7.5 cells were transfected with the pMah or pAnap DNA plasmid 24 hours 
before the RNA transfection. Cells were washed twice and 2 mL of serum-free (SF) 
medium was added to each plate. Next, 50 μL of DMRIE-C transfection reagent 
(Invitrogen) and 4 μL of RNA transcripts were mixed lightly. Transfection mixes were 
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then added to cells along with either 1 or 10 μM of the unAA (1 μM Anap; 10 μM AzF) 
and incubated for 3 hours.  Following incubation, cells were washed 2 times and 7 mL of 
DMEM(comp) supplemented with 10 μM of the respective unAA was added to each plate.  
Cells were incubated for 72 hours before supernatants were collected and clarified.   
2.13 Determination of Infectious Titre  
At 48 hours pre-infection, Huh-7.5 cells were transfected with the DNA plasmid 
coding for the tRNA/synthetase.  At 24 hours pre-infection, 50,000 transfected Huh-7.5 
cells were plated in 8-well chamber slides (ThermoFisher) in 400 l DMEMcomp and 
incubated overnight. To determine virus titre, clarified transfection supernatants were 
serially diluted 10-fold and 100 L of each dilution were inoculated in triplicate in 
chamber slides containing pMah-transfected Huh-7.5 cells and incubated for 4 hours 
before DMEMcomp was added and cells were incubated for an additional 72 hours.  Focus-
forming units were counted after 72 hours using a Zeiss Axio Imager M2 microscope 
after immunofluorescence staining.  Infectious titres were determined in triplicate and 
averaged to yield the supernatant titre.   
2.14 Immunofluorescence Staining 
At 72 hours post-infection supernatants and plastic chambers were removed.  
Slides were dipped in 10% phosphate buffered saline (PBS; Invitrogen) for 2 minutes, 
fixed in acetone for 1½ minutes and rubber gaskets removed.  The primary antibody, 
mouse anti-HCV core monoclonal antibody (B2; Anogen), was diluted 1:200 in 5% BSA 
in PBS solution and 25 L was placed on each well.  Slides were covered with a glass 
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cover slip (ThermoFisher) and incubated for 20 minutes.  Slides were dipped in PBS for 1 
minute to remove the cover slip and then washed in PBS for 5 minutes. Secondary 
antibody, Alexa Fluor  488 (Invitrogen) or Alexa Fluor  594 (Invitrogen), was diluted 
1:100 in PBS and 25 L was placed on each well.  Slides were covered with a glass cover 
slip and incubated for 20 minutes.  Slides were dipped in PBS for 30 seconds to remove 
cover slip and then washed in PBS for 5 minutes.  Slides were stained with Vectashield 
Hardset mounting medium containing DAPI (Vector Labs) and covered with a glass 
cover slip.  Once the Vectashield had dried, slides were examined using a Zeiss Axio 
Imager M2 microscope and observed using the 20X objective.   
2.15 G418 Treatment 
 To determine the effect of G418 on pAnap-transfected Huh-7.5 cells, 200,000 
Huh-7.5 cells were plated in 2-well chamber slides (ThermoFisher) in 2 ml DMEMcomp 
and incubated overnight. After 24-hours Huh-7.5 cells were transfected with pAnap and 
incubated for 24 hours before treatment with G418.  pAnap-transfected cells were then 
treated with 75 g/mL G418 and incubated overnight.  After 24-hours G418 treated, 
pAnap-transfected Huh-7.5 cells were transfected with L755X, L758X, and A761X 
encoded RNA.  Anap was added to the cells during the RNA transfection to ensure the 
possibility of incorporation during translation.  In addition, cells were maintained in 
G418 during the RNA transfection.   Following the 48-hour incubation after the RNA 
transfection, cells were fixed and visualized by indirect immunofluorescence.   
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2.16 G418 Titration 
 100,000 Huh-7.5 cells were plated in a 24-well plate in 1 mL DMEMcomp and 
incubated overnight. On the following day, cells were treated, in triplicate, with 
increasing concentrations of G418.  The concentrations used for the titration were 0 
g/mL, 10 g/mL, 20 g/mL, 40 g/mL, 60 g/mL, 80 g/mL, and 100 g/mL. After 48 
hours, the supernatant was removed and the cells were washed with 300 L of trypsin.  
Cells were then incubated for 6 minutes in 300 l of trypsin.  Following the 6 minute 
incubation, 500 l DMEM(comp) was added to the wells to inactivate the trypsin and the 
total volume was transferred to 12 mL round bottom tubes.  Cells were then counted 
using a hemocytometer.   
2.17 Transfection of Core Mutants 
 At 24-hours before the DNA transfection, 300,000 Huh-7.5 cells were plated in 2-
well chamber slides and incubated overnight. Transfection mix A was made from 50 μL 
of Optimem medium (Gibco) and 1.5 μL of Lipofectamine®3000 (Thermo Fisher 
Scientific).  Transfection mix B was made from 50 μL of Optimem medium, 2 μL of 
P®3000, and 1 μg of pAnap was added and mixed gently.  Both mixes were aliquoted for 
the number of mutants being tested, and respective DNA (wild-type core, core mutants 
and GFP) was added to mix B. Transfection mixes were then combined and incubated for 
15 minutes at room temperature.  Culture fluids were replaced by 1 mL of Optimem 
medium/well. The combined transfection mix was then added to cells along with 10 M 
Anap and incubated for 3 hours.  Following incubation, medium was replaced with 2 mL 
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of DMEM(comp).  Anap was added at a concentration of 10 M and transfected cells were 
incubated for 48 hours before being fixed and stained for immunofluorescence.   
Chapter 3: Results 
3.1 Mutant Selection:  
The first step that was necessary for unAA incorporation into p7 was the selection 
of potential sites for substitution.  We wanted to select sites that could potentially tolerate 
the substitution of a variety of unAAs.  Given that different unAAs have varied side 
chains, making them useful for a number of different applications, we wanted to select a 
wide variety of amino acid residues to account for various structural substitutions. This 
selection process yielded a panel of 14 mutants that could potentially be used for different 
unAAs.  One unAA that we would be working with was AzF and as such, a select 
number of our mutants had phenylalanine → TAG substitutions. The other unAA that we 
would be working with, for the purpose of protein tracking, was Anap.  We selected 
tryptophan and tyrosine residues to potentially accommodate the substitution of Anap 
based on their moderate structural similarity.  In addition to those amino acids, we also 
selected various others to test amenability to incorporation. To maximize the potential for 
successful incorporation, we selected residues spanning both transmembrane domains.  
We avoided making any potential substitutions in the cytoplasmic loop, since our 
previous mutational studies had shown those residues to be essential for activity77. The 
selected mutations were: L755X, L758X, A761X, L769X, Y771X, F772X, F775X, 
F776X, W780X, Y792X, T790X, W798X, F800X, and P808X.  Once the mutants were 
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designed, site-directed mutagenesis using custom primers was performed to introduce the 
mutations into the viral genome. The mutated HCV plasmids were digested using a 
restriction enzyme to confirm sequence similarity with the JFH1T template (Fig. 3.1). All 
successfully mutated plasmid constructs were validated by Sanger sequencing at The 
Center for Applied Genomics. Cloning of some mutants turned out to be problematic and 
those will be revisited in the future using more elaborate cloning procedures.   
3.2 The Effect of AzF Incorporation on Viral Infection:  
AzF is a chemically active unAA that can be used for various functions, including 
binding a fluorophore. Attaching a fluorophore directly to a residue within the p7 protein 
would allow us to visualize the protein without the use of a tag. To determine whether an 
unAA could be successfully incorporated into the HCV genome, we transfected pMah, 
the DNA plasmid coding for the tRNA and synthetase specific for AzF, followed by 
transfection of mutated RNA 24-hours post-pMah transfection.  Cells were cultured with 
AzF during the RNA transfection to ensure the possibility of unAA incorporation during 
translation. Transfected cells were harvested three days post-transfection and seeded into 
8-well chamber slides for 3 days.  The HCV core protein was detected in L758X + AzF 
virus, and A761X + AzF virus but not in L755X + AzF or L769X + AzF (Fig. 3.2).  We 
postulated that the unnatural amino acid was successfully incorporated into L758X + AzF 
virus, and A761X + AzF virus given that the HCV core protein was detected.  If the 
unAA wasn’t incorporated, translation should terminate at the stop codon located in the 
p7 sequence resulting in no core staining. Although core is upstream of p7, it won’t be 
produced in the absence of AzF given that HCV is translated as a polyprotein.  
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Figure 3.1 DNA gel of maxi prepared samples following PvuII digestion. The 
presence of bands at the same places when compared to the template JFH1T confirms that 
all mutated versions of the plasmid were intact.   
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Figure 3.2: The Effect of AzF Incorporation on Virus Infection.  1x106 Huh-7.5 cells 
were transfected with JFH1T, L755X, L758X, A761X, L769X or GDD encoded RNA. 
Cells were fixed and probed with DAPI (blue) and a specific HCV core antibody, by 
indirect immunofluorescence (green) after 72 hours, observed using the 20X objective. 
The pictures shown are representative of the entire area of the well.   Results shown are 
representative of 2 independent experiments.   
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These results were compared to the wild-type JFH1T, which showed expected levels of 
viral spread, and to ΔGDD, containing a deletion in the active site of NS5B, representing 
the replication-defective negative control for the experiment.   
3.3 The Effect of AzF on Virus Production: 
The effect of AzF incorporation on virus production was determined by measuring the 
levels of infectious virus titre using a focus-forming unit assay.  Three days post-infection 
viral titres were analyzed. JFH1T- L755X -AzF, JFH1T-L758X - AzF, JFH1T-A761X - 
AzF, JFH1T-L769X - AzF, represent the system negative controls, i.e., without the unAA 
present, translation should terminate at the amber codon. Variants with or without AzF 
produced very low levels of infectious titre when compared to the wild-type JFH1T (Fig. 
3.3).  No infectious virus was detected in GDDG + AzF, L769X + AzF, and 
L769X - AzF. Infectious virus was detectable in L755X - AzF, L758X - Anap, and 
A761X - Anap; this was unexpected given that translation should terminate at the amber 
stop codon in the absence of the unAA. As we weren’t able to visualize the unAA at this 
point, we couldn’t confirm that the successful virus production was due to unAA 
incorporation as opposed to read-through or reversion of mutations.  
3.4 Rationale for Using Anap Instead of AzF  
Although it appeared as though we had incorporation of AzF in our initial trials, 
without the addition of a fluorophore, we couldn’t easily confirm that the unAA had been 
successfully incorporated.  We couldn’t eliminate the possibility of read-through or 
reversion events in our first trial with AzF without some way to distinguish where in the  
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Figure 3.3 The effect of AzF on Virus Production. Culture fluids from cells transfected 
with JFH1T, L755X, L758X, A761X, L769X and ∆GDD were collected 72 hours post-
transfection, serially-diluted, and used to infect naïve Huh-7.5 cells that had been pre-
transfected with pMah. JFH1T and JFH1T-∆GDD-transfected cells were used to infect 
naïve Huh-7.5 cells that had not been pre-transfected with pMah.  Seventy-two hours 
post-infection cells were fixed and probed for the presence of core protein in order to 
determine the number of focus-forming units (ffu) per mL of supernatant. Viral titres 
were measured in triplicate. Results shown are representative of 1 experiment.   
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pMah-transfected Huh-7.5 cells the unAA was being incorporated.  We surmised that we 
could overcome this issue by testing the amenability of specific amino acid positions to 
incorporation of an unAA using a fluorescent unAA. Based on the literature, we decided 
that switching to Anap, a fluorescent unAA, would also make conducting localization 
studies significantly easier, since it would eliminate the need for a p7-specific antibody. 
3.5 Anap incorporation in Huh-7.5 cells 
To test whether Anap could be incorporated into the HCV genome we transfected 
pAnap, followed by transfection of RNA 24 hours post-transfection of pAnap.  Anap was 
added during the RNA transfection to ensure the possibility of incorporation during 
translation. Transfected cells were harvested three days post-transfection and seeded into 
8-well chamber slides and cultured for 3 days. Anap fluorescence was visible in L755X 
+Anap, L758X +Anap, A761X +Anap, and L769X +Anap (Fig. 3.4).  The presence of  
fluorescence confirmed incorporation of the unAA, however, since these slides were not 
stained for HCV core, it cannot be confirmed whether incorporation was into the HCV 
genome or into cellular proteins. We did not stain for core during this experiment given 
that the secondary antibody we normally used in our lab, Alexa Fluor  488, would 
fluoresce at the same wavelength as Anap.  Any green staining observed with this 
secondary antibody would result in undistinguishable results, since we wouldn’t be able 
to discriminate between Anap incorporation versus core fluorescence.  Therefore, in 
subsequent experiments, HCV core protein was visualized using a different secondary 
antibody that fluoresced red, i.e., Alexa Fluor  594. 
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Figure 3.4 Anap fluorescence was visible in transfected Huh-7.5 cells.  At 48 hours 
pre-RNA transfection, Huh-7.5 cells were transfected with pAnap.  At 24 hours pre-RNA 
transfection, 50,000 pAnap-transfected Huh-7.5 cells were plated in 8-well chamber 
slides in 400 l DMEMcomp and incubated overnight. The pAnap-transfected Huh-7.5 
cells were then transfected with JFH1T, L755X, L758X, A761X, L769X and ∆GDD 
encoded RNA. Seventy-two hours post-transfection, cells were fixed and probed with 
DAPI (blue).  GDD and JFH1T were probed with a specific HCV core antibody, by 
indirect immunofluorescence (green), observed using the 20X objective. The green 
visible in well containing L755X + Anap, L758X + Anap, A761X + Anap, and L769X + 
Anap was the fluorescence emitted by the unAA itself.   The pictures shown are 
representative of the entire area of the well.   
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3.6 Rationale for scale down of Anap experiments  
One potential issue that we wanted to address was the transfection efficiency of 
Huh-7.5 cells. Huh-7.5 cells generally have a low transfection efficiency, and up to this 
point, our experimental setup required the initial DNA transfection as well as an 
additional DNA transfection when setting up chamber slides for immunofluorescence.  
We were transfecting cells with the DNA plasmid to then be seeded into 8-well chamber 
slides for immunofluorescence.  In addition to the issues with transfection efficiency, we 
wondered if it would be possible to cut down the time it takes between starting an 
experiment and staining the slides for immunofluorescence.  Given that we were now 
working with a fluorescent unAA, our results are based on the images that we get 
following visualization on the microscope. At this point, we decided that it would be 
optimal to perform the entire experiment in 2-well chamber slides to eliminate the need 
for the additional transfection step.  Scaling down the experiment into these 2-well 
chamber slides would allow us to do both the DNA and RNA transfections directly into 
the slides, followed by immunofluorescence staining directly on the slides.  This scale 
down took the experimental set up from an 8-day protocol to a 5-day protocol.  We 
continued using the 2-well chamber slides for the duration of our experiments.   
3.7 Anap was detected in transfected cells stained for core 
To test incorporation of Anap into the HCV genome, Huh-7.5 cells were transfected with 
pAnap, followed by transfection of mutated RNA 24 hours post-pAnap transfection into 
2-well chamber slides.  Anap was added during the RNA transfection to allow 
incorporation during translation.  Transfected cells were fixed and stained 2 days after the 
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RNA transfection and visualized by indirect immunofluorescence.  GDD and JFH1T 
represent our experimental controls, with high levels of HCV core in cells transfected 
with JFH1T, and no HCV core detected in cells transfected with GDD.  We included an 
additional control in this experiment, the ‘transfected cells’ well to determine how much 
background Anap fluorescence is detectable when cells are transfected with pAnap in the 
absence of viral RNA.  As seen in the panel ‘transfected cells’ well, it is evident that 
there is background expression which may be attributed to incorporation into cellular 
proteins.  No HCV core was detected in L769X in the presence or absence of Anap.  
HCV core was detected in L755X, A761X, and L758X in the presence and absence of 
Anap (Fig. 3.5).  The fact that there was HCV core detected in the absence of Anap 
confirms that reversion or read-through was occurring. We expected we would be able to 
distinguish successful incorporation from any read-through or reversion events since 
incorporation would be characterized by the presence of green from Anap in the same 
location as red from HCV core staining. We were unable to isolate any HCV core 
positive cells containing green fluorescence from Anap.   
3.8 Treatment of DNA transfected cells with G418 
Since we encountered the issue of HCV core being detected in cells that did not 
contain Anap, we wanted a way to isolate the DNA transfected cells to maximize the 
chance of DNA transfected cells then being transfected with RNA.  The DNA plasmid 
for the tRNA/synthetase (pAnap) also encodes the gene for G418 resistance so treatment 
of transfected cells with G418 should result in cell death of any cells that weren’t 
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Figure 3.5 Anap fluorescence was detected in transfected Huh-7.5 cells stained for 
core. To determine if Anap fluorescence is detectable, 200,000 Huh-7.5 cells were plated 
in 2-well chamber slides in 2 ml DMEMcomp and incubated overnight. After 24 hours, 
Huh-7.5 cells were transfected with pAnap.  After 48 hours, pAnap-transfected Huh-7.5 
cells were transfected with RNA representing JFH1T, L755X, L758X, A761X, L769X, 
and ∆GDD. An additional control was included to determine if background Anap was 
detectable, the ‘transfected cells’ well was pAnap-transfected cells in the absence of any 
viral RNA.  Forty-eight hours post-RNA transfection, cells were fixed and probed with 
DAPI (blue) and a specific HCV core antibody, by indirect immunofluorescence (red), 
observed using the 20X objective. The green that was visible was the fluorescence 
emitted by the unAA, Anap.  The pictures shown are representative of the entire area of 
the well.  Results shown are representative of 3 independent experiments.    
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transfected with the plasmid. To test the impact of G418 on our transfected Huh-7.5 cells, 
24 hours post-pAnap transfection, we treated our cells with 75 g/ml G418 (Thermo 
Fisher Scientific).  We selected this concentration of G418 based on previous work done 
on Huh-7.5 cells.  Twenty-four hours post-treatment with G418 we transfected Huh-7.5 
cells with RNA representing L755X, L758X and A761X.  Anap was added during the 
RNA transfection to allow incorporation during translation.  Transfected cells were fixed 
and stained 2 days after the RNA transfection and visualized by indirect 
immunofluorescence. Low levels of HCV core were detected in L755X and A761X + 
Anap, without the addition of G418 (Fig 3.6).  No Anap fluorescence was detected in 
either L755X or A761X.  Due to an experimental error, we were unable to get an image 
of L758X + Anap, without the addition of G418.  There was an evident reduction in the 
number of cells present following treatment with G418, however, the treated cells looked 
unhealthy. Anap fluorescence was detected in L755X, L758X and A761X; however, 
there was no HCV core detected in any of the samples following the G418 treatment.  
This result confirmed more work was needed to determine the ideal concentration of 
G418 to work with. 
3.9 G418 Titration Experiment  
Despite seeing a reduction in total cells, the G418 treatment seemed to have an impact on 
the quality of cells. A titration experiment was performed to determine what  
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Figure 3.6 Treatment of transfected Huh-7.5 cells with G418. At 24 hours pre-pAnap 
transfection, 200,000 Huh-7.5 cells were plated in 2-well chamber slides in 2 mL 
DMEMcomp and incubated overnight. After 24 hours, Huh-7.5 cells were transfected with 
pAnap.  At 48 hours, pAnap-transfected Huh-7.5 cells were treated with 75 g/mL G418 
and incubated.  After 24-hours, pAnap-transfected, G418 treated cells were transfected 
with RNA representing L755X, L758X, and A761X. Untransfected, and untreated Huh-
7.5 cells were transfected with RNA representing JFH1T and GDD.  Forty-eight hours 
post-RNA transfection, cells were fixed and probed with DAPI (blue) and a specific HCV 
core antibody, by indirect immunofluorescence (red) and observed using the 20X 
objective. The green that is visible is the fluorescence emitted by the unAA, Anap.  The 
pictures shown are representative of the entire area of the well. Results shown are 
indicative of 1 experiment.   
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concentration of G418 results in 50% Huh-7.5 cell death, in the interest of potentially 
establishing a cell line stably-transfected with pAnap.  To determine what the ideal 
concentration of G418 was, 100,000 Huh-7.5 cells were plated into each individual well 
in a 24-well plate.  The cells were then treated, in triplicate, with increasing 
concentrations of G418: 0 g/mL, 10 g/mL, 20 g/mL, 40 g/mL, 60 g/mL, 80 g/mL 
and 100 g/mL (Fig. 3.7).  The well containing 0 g/mL is representative of 100% cell 
growth given that there is no inhibition.  Based on the results obtained, we estimated that 
50% cell death would be obtained at a G418 concentration of 65 g/mL. Any future 
experiments using G418 for selection of Huh-7.5 cells will be done using a concentration 
of 65 g/ml. 
3.10 Huh-7.5 cells transfected with pAnap and JFH1T 
 During the treatment of Huh-7.5 cells with G418 experiment, we noted that there 
was no HCV core detected in any of the samples following the G418 treatment.  Given  
that we had detected HCV core in previous experiments, we considered the possibility 
that cells that are successfully transfected with pAnap may not be amenable to 
transfection with RNA representing JFH1T. To determine if it was possible to have 
pAnap-transfected cells also get transfected with virus, we transfected Huh-7.5 cells with 
pAnap, and then after 24 hours we transfected those cells with RNA representing wild-
type JFH1T.  Anap was added during the RNA transfection to demonstrate which cells 
were successfully transfected with pAnap. The ‘transfected cells’ well represents a virus 
negative control, and is representative of typical levels of background incorporation of 
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Figure 3.7 G418 Titration. 100,000 Huh-7.5 cells were plated in 1 mL DMEMcomp and 
incubated overnight.  After 24 hours the cells were treated, in triplicate, with increasing 
concentrations of G418: 0 g/mL, 10 g/mL, 20 g/mL, 40 g/mLl, 60 g/mL, 80 
g/mL, and 100 g/mL.  After 48 hours, cells were trypsinized and counted.   
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Anap into cellular proteins. There were comparable levels of RNA transfection when 
comparing transfection of JFH1T into Huh-7.5 cells and pAnap-transfected Huh-7.5 cells 
(Fig. 3.8).  Despite the moderate level of RNA transfection, there was no clear overlap 
between HCV core staining and Anap fluorescence. Based on this result, we concluded 
that the experiment should be repeated with an additional infection of pAnap transfected 
cells with JFH1T.    
3.11 DNA transfected Huh-7.5 cells can be transfected and infected with JFH1T 
 Although there was no clear overlap between the Anap fluorescence and HCV 
core staining during our first trial with JFH1T transfection, we wanted to determine if 
pAnap-transfected cells could be infected with wild-type JFH1T.  To test this, 200,000 
Huh-7.5 cells were plated in 2-well chamber slides.  After 24-hours, Huh-7.5 cells were 
transfected with pAnap and incubated overnight.  After 24 hours, pAnap-transfected cells 
were either transfected with RNA representing JFH1T or infected with JFH1T. Anap was 
added during the RNA transfection or infection to demonstrate which cells had been 
successfully transfected with pAnap.  Forty-eight hours later, cells were fixed and stained 
to be visualized by indirect immunofluorescence.  As a control, non-pAnap-transfected 
Huh-7.5 cells were transfected with GDD and JFH1T and also infected with JFH1T.    
There was evident overlap between Anap fluorescence and HCV core staining when 
pAnap-transfected cells were transfected or infected with JFH1T (Fig. 3.9).  This overlap 
indicates that the cells that were successfully transfected with pAnap, could also be 
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Figure 3.8 DNA transfected Huh-7.5 cells, transfected with WT JFH1T + ANAP. 
200,000 Huh-7.5 cells were plated in 2 well chamber slides in 2 mL DMEMcomp and 
incubated overnight.  After 24 hours the cells were transfected with pAnap.  After 48 
hours, we transfected the cells with RNA representing wild-type JFH1T or GDD.  Anap 
was added during the RNA transfection to identify which cells were successfully 
transfected with the pAnap.  Forty-eight hours post-RNA transfection, cells were fixed 
and probed with DAPI (blue) and a specific HCV core antibody, by indirect 
immunofluorescence (red) and observed using the 20X objective. The green that is 
visible is the fluorescence emitted by the unAA, Anap. The pictures shown are 
representative of the entire well.  The results are representative of one experiment.  
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infected or transfected with JFH1T.  This excluded the possibility that there was any 
mutual exclusion between the virus and pAnap.  
3.12 Testing incorporation of Anap into the HCV core protein  
One obstacle we encountered when testing incorporation of unAA into the p7 
protein in the context of the full virus was that even if unAA was successfully 
incorporated into p7, we did not know what to expect regarding the localization of p7. It 
was possible that unAA could get incorporated, but since the normal localization pattern 
of p7 is not known, we had no way of knowing whether what we were seeing would have 
been correct.  In addition, we were testing incorporation in the context of a full 
replicating virus, and were thus limited by the fact that mutations could arise eliminating 
our inserted UAG codon in the viral RNA. Despite this limitation, we saw that an 
individual cell that was transfected with pAnap could also be transfected or infected with 
JFH1T.  Since mutual exclusion didn’t appear to be the main problem, we decided to test 
Anap incorporation in a single protein expression system. We concluded that using a 
single-protein expression system would facilitate the selection of potential amenable sites 
to unAA incorporation since the potential for mutations would be eliminated.  Since there 
is a reliable antibody for core staining, following incorporation of Anap, cells could be 
stained for core and images overlaid to show that 
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Figure 3.9 DNA transfected Huh-7.5 cells transfected and infected with JFH1T. To 
set-up, 200,000 Huh-7.5 cells were plated in 2 well chamber slides in 2 mL DMEMcomp 
and incubated overnight.  After 24 hours, the cells were transfected with pAnap.  After 48 
hours various samples of cells were transfected with RNA representing either wild-type 
JFH1T or GDD and also infected with JFH1T. Forty-eight hours post-RNA transfection 
or infection, cells were fixed and probed with DAPI (blue) and a specific HCV core 
antibody, by indirect immunofluorescence (red) and observed using the 20X objective. 
The green that is visible is the fluorescence emitted by the unAA, Anap. The top row of 
panels represents the controls for the experiment: panel A is untransfected Huh-7.5 cells; 
panel B is Huh-7.5 cells infected with JFH1T; panel C is Huh-7.5 cells transfected with 
GDD and panel D is Huh-7.5 cells transfected with JFH1T.  The bottom row of panels 
are the experimental wells: panel E is pAnap-transfected Huh-7.5 cells; panel F is pAnap-
transfected Huh-7.5 cells infected with JFH1T; panel G is pAnap-transfected Huh-7.5 
cells transfected with GDD and panel H is pAnap-transfected Huh-7.5 cells transfected 
with JFH1T. The pictures shown are representative of the entire well.  
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core staining and Anap fluorescence were in the same location.  Given that p7 cannot be 
easily visualized, trying to incorporate an unAA into the HCV core protein would make 
the most sense.  A major advantage to incorporating Anap into core is that it can be easily 
confirmed whether Anap disrupts core localization based on where core staining appears 
since we know where core should be. We postulate that if Anap does not disrupt core 
localization, it may not affect function either.  
3.13 Core Mutant Selection  
The first step was the selection of potential sites for incorporation within the HCV 
core protein.  As with p7, we wanted to select sites that could potentially tolerate the 
substitution of a variety of unAAs. This selection process yielded a panel of 11 mutants 
that could be used for different unAAs.  As previously mentioned, some work was done 
with AzF and as such, a select number of our mutants had phenylalanine → UAG 
substitutions.  We selected any tryptophan and tyrosine residues to account for the 
substitution with Anap, given that they are the most structurally similar. To maximize the 
potential for successful incorporation, we selected residues throughout the core protein. 
The selected mutations were: F24X, F130X, W76X, W83X, W93X, W96X, W107X, 
Y35X, Y86X, Y136X, and Y164X. Once the mutants were designed, plasmids were 
ordered from Genscript. 
As part of an Honour’s project, Bridgette Green performed some preliminary 
work with the F24X, F130X, W76X and W86X mutants to optimize the concentration of 
Anap to be used.  It was found that using a concentration of 10 μM was ideal, and all 
subsequent work using Anap was performed at this optimal concentration. 
  58 
3.14 Incorporation of Anap into Core Mutants  
 Since we had shifted to using a single protein expression system, we were able to 
condense the transfection protocol to a one-day procedure because both pAnap and the 
core mutant plasmids are DNA plasmids.  To test Anap incorporation, 300,000 Huh-7.5 
cells were plated in 2 well chamber slides in 2 mL DMEMcomp and incubated overnight.  
After 24 hours, the cells were transfected with both pAnap and individual core mutant 
plasmids. Wild-type core was used as a positive control for successful protein expression 
and comparison of core protein localization during this experiment.  Two transfection 
controls were also included during the experimental setup. A negative control, cells only, 
had the transfection reagents in the absence of any DNA.  A positive control, GFP, was 
included to confirm successful transfection by the presence of green fluorescence.  The 
transfection controls were consistent; the untransfected cells showed no fluorescence 
detected, and the GFP control shows green fluorescence indicating a successful 
transfection (Fig 3.10a).  The wild-type core sample had high levels of core staining 
detected in the absence and presence of Anap.  In order to ensure all samples were treated 
the same way, the Huh-7.5 cells to be transfected with wild-type core were also 
transfected with pAnap and incubated in the presence and absence of Anap.  We expected 
this high expression in both absence and presence of Anap given that translation of the 
wild-type core plasmid is independent of Anap incorporation since there was no specific 
mutation site included in the protein sequence.  Images of the tryptophan mutants that we 
screened for any amenable positions to unAA incorporation indicate successful 
incorporation (Fig 3.10a).  All of the tryptophan mutants that we tested for Anap  
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Figure 3.10a Incorporation of Anap into core mutants: transfection controls.  To set-
up, 300,000 Huh-7.5 cells were plated in 2 well chamber slides in 2 mL DMEMcomp and 
incubated at 37C in 5% CO2.  After 24 hours, as controls, cells were either transfected 
with the plasmid containing GFP or mock transfected in the absence of DNA plasmid. 
Forty-eight hours post-transfection, slides were fixed and probed with DAPI (blue) and a 
specific HCV core antibody, by indirect immunofluorescence (red) and observed using 
the 20X objective. The green that is visible is the fluorescence emitted by GFP.   
 
 
 
 
 
 
 
 
 
  60 
incorporation were successful in expressing core (Fig. 3.10b). In W83X, W93X and 
W107X, the HCV core protein was only detected in the presence of Anap.  The red 
staining shows the typical perinuclear staining of core and the Anap fluorescence co-
localizes with it indicating that the unAA is actually being incorporated into the core 
protein.  There was very clear overlap of the green fluorescence from Anap and the core 
staining in W93X and W107X in the presence of Anap.  An important point to note here 
is that, although the emission is faint in W83X and W96X, Anap fluorescence was 
detected in each of the tryptophan mutants, and overlapped with the HCV core staining, 
indicating successful Anap incorporation.  W96X was positive in the presence and 
absence of Anap.  This was not expected, as expression of the protein should not occur in 
the absence of Anap as translation should terminate at the unique amber stop codon.  We 
postulate that this might have been an instance of contamination. As seen with the 
tryptophan mutants, Y35X, Y136X and Y164X in the presence of Anap showed 
successful incorporation of Anap into the core protein (Fig. 3.10c).  There is very clear 
co-localization of the green fluorescence from Anap and the core staining in Y35X and 
Y136X in the presence of Anap.  The fluorescence of Anap is not evident in Y164X in 
the overlay image, however it is evident in the panel containing only Anap that it is 
present. The images shown in Fig. 3.10b and c are all from the same experiment, but 
results were presented as groups based on the original amino acid substituted. The images 
generated from the wild-type core-  
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Figure 3.10b Incorporation of Anap into core mutants: tryptophan mutants. To test 
incorporation into the HCV core proteins, 300,000 Huh-7.5 cells were plated in 2 well 
chamber slides in 2 mL DMEMcomp and incubated overnight.  After 24 hours, cells were 
transfected with pAnap, along with the plasmid encoding W83X, W93X, W96X, and 
W107X core mutants. In addition, we also transfected cells with wild-type core as a 
positive control.  As a negative control, each mutant was transfected in the absence of 
Anap, which is shown on the far right as a ‘no Anap’ panel; this panel is an overlay 
image of DAPI, Anap and core staining. Forty-eight hours after the transfection slides 
were fixed and probed with DAPI (blue) and a specific HCV core antibody, by indirect 
immunofluorescence (red). The green that is visible is the fluorescence emitted by Anap.  
Results shown are representative of 2 independent experiments.  
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Figure 3.10c Incorporation of Anap into core mutants: tyrosine mutants. To test 
Anap incorporation into the HCV core protein, 300,000 Huh-7.5 cells were plated in 2 
well chamber slides in 2 mL DMEMcomp and incubated overnight.  After 24 hours, cells 
were transfected with pAnap, along with the plasmids encoding Y35X, Y136X, and 
Y164X core mutants. Cells were transfected with wild-type core as a positive control. As 
a negative control, each mutant was transfected in the absence of Anap, which is shown 
on the far right as a ‘no Anap’ panel; this panel is an overlay image of DAPI, Anap and 
core staining.  Forty-eight post-transfection slides were fixed and probed with DAPI 
(blue) and a specific HCV core antibody, by indirect immunofluorescence (red). The 
green that is visible is the fluorescence emitted by Anap.  Results shown are 
representative of 2 independent experiments.   
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transfected cells were duplicated in the figures.  Based on these results, we concluded that 
it was possible to incorporate Anap into the HCV core protein.     
3.15 Core Positive Cells Detected 
 In order to return to the context of the full virus with a potential position that is 
likely to work, we needed to develop a way to determine which mutants were most 
successful. In order to accomplish this, we counted each cell that was positive for core 
and checked to see if that cell also exhibited green fluorescence indicating the presence of 
Anap to note any discrepancies (Fig. 3.11).  We believe there might be some cases where 
the core staining was blocking or obstructing the Anap fluorescence.  With the exception 
of the wild-type core, W96X + Anap had the highest number of core positive cells.  The 
lowest count of core positive cells was detected in Y35X in the presence of Anap. W83X, 
W93X, W107X, Y136X and Y164X, in the presence of Anap, all had comparable levels 
of core positive cells.  During the counting process, the W96X -Anap core positive cells 
could not be located, potentially due to obstruction from older Vectashield or DAPI stain 
diffusing out.  Based on the results, W83X, W96X, and Y164X might be most likely to 
work in the context of the full virus.   
Chapter 4: Discussion  
 
The role of the HCV p7 protein remains controversial due in part to the limitations of 
current protein labelling methods.  A novel method of protein labelling could be achieved 
through the incorporation of an unAA into the target protein. As mentioned above,  
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Figure 3.11 Relationship between Anap and Detected HCV core staining. 
Immunofluorescence slides from the previous experiment were scored for the number of 
HCV core-positive cells (red bar), as well as core-positive cells with corresponding Anap 
fluorescence (green bar) representing potential contamination or read-through. 
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unAAs have been used to expand the genetic code in a number of organisms137.  Different 
groups have utilized this technique in a variety of applications including probing protein-
protein interactions, visualization of target proteins, and controlling protein functions in 
live vertebrates137.  Although this technique has been extensively used, it has not yet been 
applied for visualization of viral proteins137.  The rationale behind our experiments was 
that incorporation of an unAA that could have a fluorophore attached, or that is 
inherently fluorescent, would allow visualization of the protein of interest. 
Although we selected a panel of 14 mutants to screen for their amenability to 
unAA incorporation, site-directed mutagenesis only yielded 4 successfully cloned 
mutants.  We performed numerous attempts to clone the additional 10 mutants, however, 
we were unsuccessful.  Despite this setback we attempted incorporation of an unAA 
using the 4 mutants we had cloned, given that a variety of residues have been substituted 
with unAAs in the literature.  The 4 mutants that were successfully cloned were L755X, 
L758X, A761X, and L769X.  We used these 4 mutants to attempt unAA incorporation of 
AzF into the p7 protein in the context of a replicating virus.  We selected AzF for our 
preliminary trials given that it has a chemically active side chain that can be utilized in a 
number of different reactions.  One potential use for AzF is probing protein-protein 
interactions using the photocrosslinking capabilities of AzF, an aryl-azide.  Another 
potential application of AzF is visualizing a target protein; a click-chemistry reaction to 
attach a fluorophore directly onto the unAA could be used for localization.  This click-
chemistry reaction would be accomplished via an azide-alkyne cycloaddition; the azide is 
provided by the unAA, and the alkyne would be from an alkyne-dye, such as a 
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fluorophore.  Before we could utilize AzF for a click-chemistry reaction, we had to first 
successfully incorporate AzF into p7.  Our first trial suggested that we had successful 
incorporation of the AzF given that we saw core-positive cells in L758X, and A761X 
(Fig. 3.2). The first trial had one major drawback which we addressed in all subsequent 
experiments; we hadn’t included a control for the unAA incorporation system.  For future 
experiments, we realized we would need to include a control per mutant, whereby the 
cells would be transfected with the specific DNA plasmid (pMah or pAnap), followed by 
the transfection of the viral RNA, in the absence of the unAA. This would provide a 
system negative control, since translation of the polyprotein should terminate when the 
unique amber stop codon in p7 is reached.  Core-positive cells should not be detected in 
the absence of the unAA.  
Based on our preliminary screen with AzF in p7, we wanted to determine what 
effect AzF had on virus production (Fig. 3.3). Although virus was produced in L755X 
+AzF and L758X +AzF, it was evident that AzF was negatively impacting the degree of 
virus production when compared with JFH1T.  In addition, virus was produced in L755X, 
L758X, and A761X in the absence of AzF.  These results were not expected and 
unfortunate, given that virus was being produced in the mutants without AzF added, 
which should not occur.  As previously mentioned, translation should terminate at the 
amber stop codon in the absence of the unAA resulting in no virus production. At this 
point, we realized that reversion or translational read-through might be occurring.  HCV 
is a highly mutatable virus, and it was possible that the virus was mutating in order to 
eliminate the stop codon.  If mutations were occurring to alter the unique codon to be 
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specific for one of the 20 natural amino acids, translation would no longer be dependent 
on incorporation of the unAA. Another possible explanation for the core-positive cells 
detected would be read-through. Read-through is when the ribosomes misread the 
termination signal provided by a stop codon and continue translation past the stop codon. 
Although read-through events are possible, they are less likely to occur than reversion. 
Also, the degree of read-through necessary to account for the discrepancies seen is higher 
than we would expect to occur.   
To overcome this obstacle, we decided to further screen the available positions 
using a fluorescent unAA, Anap118.  Utilizing a fluorescent unAA would allow us to 
distinguish between successful incorporation and reversion/read-through events, since we 
would expect to see overlap of fluorescence from Anap and staining of core-positive cells 
when successful incorporation occurred.  We demonstrated that Anap fluorescence could 
be detected in Huh-7.5 cells following transfections with the DNA plasmid for 
incorporation and the virus encoded RNA (Fig. 3.4). During the first screening trial with 
Anap, we did not stain for HCV core given that the secondary antibody normally used in 
our lab would fluoresce at the same wavelength as Anap. During the next trial, we 
screened the same four mutants and used a HCV core specific secondary antibody that 
would be detectable at a different wavelength than Anap (Fig. 3.5).  We demonstrated 
that core-positive cells were detected, however there was no clear overlap between the 
core-positive cells and Anap fluorescence.  L755X, L758X, and A761X were all positive 
for virus production in both the presence and absence of Anap, indicating that replication 
was not dependent on incorporation of the unAA.  There was no virus detected in L769X 
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in any of our trials, so we ceased testing incorporation with this mutant in subsequent 
experiments given its consistent negative results.   
In order for replication of the mutants to occur, the transfected viral RNA must 
enter a cell that was successfully transfected with pAnap. In order to increase the chances 
of finding an event where Anap fluorescence is detected in a core-positive cell, we 
selected for cells that were successfully transfected with pAnap using G418.  The pAnap 
plasmid encodes for Geneticin (G418) resistance, therefore it should be possible to 
eliminate any nontransfected cells using G418 treatment.  We hypothesized that treating 
the cells with G418 would result in cell death of any cells not transfected with pAnap.  In 
theory, treating the cells with G418 would be beneficial since the only cells available to 
be transfected with the viral RNA would already be transfected with pAnap. 
Unfortunately, no core-positive cells were detected following treatment with G418 and 
the cells did not appear to be healthy (Fig. 3.6).  Before continuing with G418 treatment, 
we determined what concentration was optimal for use with Huh-7.5 cells (Fig. 3.7).  We 
carried a titration experiment to establish that for the Huh-7.5 cells used in our lab, the 
ideal concentration of G418 to use is 65 g/mL (Fig 3.7).   
 Since we did not detect any core-positive cells following treatment with G418, we 
considered the possibility that there was mutual exclusion between pAnap and the viral-
encoded RNA.  We postulated that it was possible that once a cell was transfected with 
the plasmid for Anap incorporation, that cell was no longer susceptible to HCV infection.  
To refute this possibility, we transfected cells with pAnap, followed by transfection with 
RNA representing wild-type JFH1T (Fig. 3.8). In the first trial with transfected cells 
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subsequently transfected with JFH1T, there were no cells that stained positive for core 
which also had detectable fluorescence from Anap.  We attributed this absence of overlap 
between core-staining and Anap fluorescence to a relatively low transfection efficiency 
with the virus and repeated the experiment.  In the second trial, we also included an 
infection of the transfected cells to eliminate the possibility of mutual exclusion.  We 
demonstrated that pAnap transfected Huh-7.5 cells could also be transfected or infected 
with JFH1T (Fig 3.9).  This confirmed that the virus could enter and replicate within a 
cell that had been transfected with the pAnap.    
Given that our issues with incorporation were not due to mutual exclusion 
between the virus and the DNA plasmid, we decided we would optimize the system using 
a viral protein in a single protein expression system before returning to the full virus.  
This technique would allow us to test incorporation into a viral protein without the 
mutational pressure of the virus.  Since there is no reliable antibody for 
immunofluorescence studies with p7, we decided that core would be an ideal target for 
optimization in a single protein expression system.  Successful incorporation of the unAA 
would be indicated by an overlap of the core-staining and the fluorescence emitted by 
Anap.  We selected a panel of 11 potential sites for incorporation and had the DNA 
plasmids synthesized.  Some preliminary work was done by another student in the lab 
using 4 of the 11 core mutants. Following success with the first 4 mutants tested (F24X, 
W76X, Y86X, and F130X), we screened the remaining 7 mutants for their amenability to 
incorporate Anap at the selected positions.  We demonstrated that Anap could be 
successfully incorporated into Y35X, W83X, W93X, W96X, W107X, Y136X, and 
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Y164X in the presence of Anap (Fig. 3.10a, b and c).  No core-positive cells were 
detected in the absence of Anap, except in the case of W96X.  Two core-positive cells 
were detected in W96X; which may have been due to contamination or read-through. No 
core-positive cells were detected in W96X in the absence of Anap in subsequent 
experiments (not shown in this thesis) supporting the belief that contamination may have 
occurred in the first trial. In addition to the 7 mutants that we screened, core-positive cells 
were also detected in the presence of Anap in the remaining 4 mutants: F24X, W76X, 
Y86X and F130X (Fig. 3.10 a, b, and c).  
Since we demonstrated successful incorporation of the unAA, Anap, into the 
HCV core protein, we evaluated the mutants based on their transfection efficiency to 
elucidate which unAAs might be ideal candidates for trials in the context of the full virus.  
We plotted the relationship between detection of Anap and the presence of a core-
positive cell (Fig. 3.11).  We postulated that the mutants with the highest number of core-
positive cells might be ideal target positions for attempting incorporation of Anap into 
core in the context of the replicating virus.  Based on these criteria, W83X, W96X, and 
Y164X might be more likely to work when we return to the full virus based on the 
number of core-positive cells that were detected.  Although the number of core-positive 
cells may provide some indication as to which mutants will be successful in the virus, it 
is more likely that structure will have the greatest impact.  Since we can’t be certain that 
the number of core-positive cells is reflective of successful incorporation in the virus, we 
will attempt to incorporate Anap into all 11 core mutants in the full virus.   
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If our attempts at incorporation of Anap into HCV core protein in the full virus 
are successful, we will be able to contribute to the growing body of research about the 
practical applications of unAA incorporation.  This would also provide a novel way to 
label viral proteins in host cells. Thus far, unAAs have been used in many different 
ways139.  One study utilized Anap incorporation to monitor the voltage-dependent motion 
of the catalytic region of voltage-sensing phosphatase in Xenopus oocytes123.  Although 
this example of Anap incorporation was not done in the context of a virus, it supports the 
fact that Anap can be very useful in localization studies.   
4.1 Future Applications 
Once we have optimized the system so that Anap can be incorporated into HCV 
proteins in the full virus, we can expand this method to include other viruses as well.  
Theoretically, this technique could be applied to any viral protein and could be used for 
localization and co-localization studies. One interesting application using fluorescent 
unAAs would be incorporating multiple different fluorescent unAAs into different viral 
proteins.  One group has proved that unAA incorporation into viruses is possible through 
the establishment of a system to control multicycle replication of live-attenuated HIV-1 
by incorporating AzF138. The Guo group sought to improve the safety of live-attenuated 
vaccines through the incorporation of AzF into selected sites in HIV-1.  They constructed 
all-in-one live-attenuated HIV-1 mutants that contained genomic copies of the amber 
suppression system necessary for unAA incorporation to impart the ability to “turn on” or 
“turn off” the virus.  They were successful in establishing a system that incorporated AzF 
at various locations.  Although, their system and ours vary in the specific aim of study, 
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this research paper provides proof of concept that unAAs can be incorporated into a 
virus. Another major difference between the two applications is that their success was 
based on cessation of virus production in the absence of AzF, whereas we are aiming to 
use the unAAs as a potential tool for viral protein labelling. This group was not interested 
in the localization or protein function applications of unAA incorporation. 
Although we have faced some challenges in developing our system of unAA 
incorporation, we remain optimistic that the system will ultimately be used successfully.  
Some of our main concerns have been based on the known low transfection efficiency of 
Huh-7.5 cells.  The Guo group had one major advantage when working with HIV since 
they were able to utilize HEK 293T cells, which are known to have high transfection 
efficiency136. This would facilitate successful incorporation of an unAA since more cells 
would be transfected with pMah. Despite this success with unAA incorporation in HIV, 
unAA incorporation has yet to be used as a tool for labelling viral proteins in host cells.  
We believe that using a fluorescent unAA for visualiziation of viral proteins would be a 
major breakthrough in the field of virology since it would eliminate the need for a 
protein-specific antibody.   
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